CIK 0001830487 · Large accelerated filer
Pharvaris N.V.
Sign in to watch- Ticker
- PHVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- other
- Phone
- 31 (0)71 203 6410
- Business address
- J.H. OORTWEG 21, 2333 CH LEIDEN, LEIDEN, Netherlands
- Former names
- Pharvaris, B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,335,217
- in 16 filings, $4.1M under 10b5-1 plans
Net −$20,335,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Schikan Johannes Gerardus Christiaan Petrus −$7.0M Director sold 64% of stake
- Lu Peng −$4.7M President sold 67% of stake
- Bjork Elisabeth −$2.0M Director sold 78% of stake
- Lesage Anne −$1.9M Chief Early Development sold 40% of stake
- Abele Stefan Andreas −$1.8M Chief Technical Ops Officer sold 54% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-14 | Lu Peng President | Shares withheld for taxes 10b5-1 | −117 | $38.02 | $4K | 64,953 |
| 2026-09-14 | Modig Berndt Chief Executive Officer | Sale 10b5-1 | −2,291 | $39.40 | $90K | 128,334 |
| 2026-09-11 | Lu Peng President | Option exercise 10b5-1 | +15,000 | $2.59 | $39K | 80,179 |
| 2026-09-11 | Lu Peng President | Sale 10b5-1 | −15,000 | $40.13 | $602K | 65,179 |
| 2026-09-11 | Lu Peng President | Shares withheld for taxes 10b5-1 | −109 | $37.51 | $4K | 65,070 |
| 2026-09-10 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +30,000 | $8.05 | $242K | 86,450 |
| 2026-09-10 | Lesage Anne Chief Early Development | Sale 10b5-1 | −30,000 | $38.30 | $1.1M | 56,450 |
| 2026-09-10 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 15,000 | ||
| 2026-09-09 | Glassman Robert Director | Option exercise 10b5-1 | +8,000 | $20.00 | $160K | 18,500 |
| 2026-09-09 | Glassman Robert Director | Sale 10b5-1 | −8,000 | $37.55 | $300K | 10,500 |
| 2026-09-09 | Glassman Robert Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 0 | ||
| 2026-09-08 | Lu Peng President | Option exercise 10b5-1 | +15,000 | $2.59 | $39K | 80,179 |
| 2026-09-08 | Lu Peng President | Sale 10b5-1 | −15,000 | $40.68 | $610K | 65,179 |
| 2026-08-14 | Modig Berndt Chief Executive Officer | Sale 10b5-1 | −2,292 | $34.77 | $80K | 130,625 |
| 2026-08-12 | Lu Peng President | Shares withheld for taxes | −117 | $34.42 | $4K | 65,179 |
| 2026-08-11 | Lu Peng President | Shares withheld for taxes | −109 | $34.84 | $4K | 65,296 |
| 2026-07-13 | Modig Berndt Chief Executive Officer | Sale 10b5-1 | −2,292 | $34.97 | $80K | 132,917 |
| 2026-07-12 | Lu Peng Chief Medical Officer | Shares withheld for taxes | −117 | $35.07 | $4K | 65,405 |
| 2026-07-11 | Lu Peng Chief Medical Officer | Shares withheld for taxes | −109 | $35.07 | $4K | 65,522 |
| 2026-06-30 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −30,712 | $35.49 | $1.1M | 315,167 |
Page 3 of 9 · 170 trades